XNAS:PCYC Pharmacyclics Inc Insider Activity 4 Filing - 1/19/2012

Effective Date 1/19/2012

XNAS:PCYC (Pharmacyclics Inc): Fair Value Estimate
Premium
XNAS:PCYC (Pharmacyclics Inc): Consider Buying
Premium
XNAS:PCYC (Pharmacyclics Inc): Consider Selling
Premium
XNAS:PCYC (Pharmacyclics Inc): Fair Value Uncertainty
Premium
XNAS:PCYC (Pharmacyclics Inc): Economic Moat
Premium
XNAS:PCYC (Pharmacyclics Inc): Stewardship
Premium
 
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
14159 capital (GP), LLC
  2. Issuer Name and Ticker or Trading Symbol
PHARMACYCLICS INC [PCYC]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
667 MADISON AVENUE, 21ST FLOOR
3. Date of Earliest Transaction (Month/Day/Year)
01/19/2012
(Street)

NEW YORK, NY US 10065
4. If Amendment, Date Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1)(2) 01/19/2012   P   594 A $16.0682 171,060 I Through Partnership(3)
Common Stock(1)(2) 01/19/2012   P   278 A $16.0686 171,338 I Through Partnership(3)
Common Stock(1)(2) 01/19/2012   P   66 A $15.8091 171,404 I Through Partnership(3)
Common Stock(1)(2) 01/20/2012   P   4,712 A $16.4096 176,116 I Through Partnership(3)
Common Stock(1)(2) 01/20/2012   P   1,824 A $16.4388 177,940 I Through Partnership(3)
Common Stock(1)(2) 01/20/2012   X   500 A $15 178,440 I Through Partnership(3)
Common Stock(1)(2) 01/20/2012   X   200 A $15 178,640 I Through Partnership(3)
Common Stock(1)(2) 01/23/2012   P   1,149 A $16.8975 179,789 I Through Partnership(3)
Common Stock(1)(2) 01/23/2012   P   1,923 A $16.8784 181,712 I Through Partnership(3)
Common Stock(1)(2) 01/23/2012   P   1,201 A $16.8399 182,913 I Through Partnership(3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Call Option $15 01/19/2012   P   5   01/19/2012 01/21/2012 Common Stock 500 $1.25 5 I Through Partnership(3)
Call Option $15 01/20/2012   P   2   01/20/2012 01/21/2012 Common Stock 200 $1.4976 7 I Through Partnership(3)
Call Option $15 01/20/2012   X     5 01/19/2012 01/21/2012 Common Stock 500 $1.25 2 I Through Partnership(3)
Call Option $15 01/20/2012   X     2 01/20/2012 01/21/2012 Common Stock 200 $1.4976 0 I Through Partnership(3)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
14159 capital (GP), LLC
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065
    X    
BAKER FELIX
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065
    X    
BAKER JULIAN
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065
    X    

Signatures

 /s/ Julian C. Baker, as Managing Member of 14159 Capital (GP), LLC   01/23/2012
** Signature of Reporting Person Date

 /s/ Julian C. Baker   01/23/2012
** Signature of Reporting Person Date

 /s/ Felix J. Baker   01/23/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) In addition to 14159 Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker each of whom has the same business address as 14159 Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).
(2) However, the Reporting Persons disclaim that they or any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons and each of them disclaim beneficial ownership or securities reported herein except to the extent of their pecuniary interest, if any, therein.
(3) Represents securities owned directly by 14159, L.P., a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are controlling members of 14159 Capital (GP), LLC.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:PCYC Pharmacyclics Inc Insider Activity 4 Filling

Pharmacyclics Inc XNAS:PCYC Stock - Get Insider Activity SEC Filing of Pharmacyclics Inc XNAS:PCYC stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

Content Partners
XNAS:PCYC Pharmacyclics Inc Insider Activity 4 Filing - 1/19/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:PCYC Pharmacyclics Inc Insider Activity 4 Filing - 1/19/2012  |  Next: XNAS:PCYC Pharmacyclics Inc Insider Activity 4 Filing - 1/24/2012